The Company The Company Promore Pharma in Brief Vision and Strategy Market Team Board of Directors Projects Projects Development Portfolio PXL01 – Prevention of Post-Surgical Adhesions LL-37 – Healing of Chronic Wounds Publications Investors Investors Promore Pharma on Nasdaq First North First North Certified Adviser The Share Shareholders Warrant Programs Share capital development Financial Reports Press Releases Presentations and Events Calendar Subscribe Corporate Governance Corporate Governance Corporate Governance Nomination Committee General Meeting General Meetings The Board of Directors Board of Directors The Management Management Remunerations and Remuneration Committee Auditor and Audit Committee Articles of Association Media Media Press Releases News Imagebank Subscribe Contact Contact Office Investors Media Svenska The Company Promore Pharma in Brief Vision and Strategy Market Team Board of Directors Projects Development Portfolio PXL01 – Prevention of Post-Surgical Adhesions LL-37 – Healing of Chronic Wounds Publications Investors Promore Pharma on Nasdaq First North First North Certified Adviser The Share Shareholders Warrant Programs Share capital development Financial Reports Press Releases Presentations and Events Calendar Subscribe Corporate Governance Corporate Governance General Meeting General Meetings Nomination Committee The Board of Directors Board of Directors The Management Management Remunerations and Remuneration Committee Auditor and Audit Committee Articles of Association Media Press Releases News Imagebank Subscribe Contact Office Investors Media PXL01 program entering Phase III clinical trial A biotech with global reach Therapeutic peptides for bioactive wound care Two first-in-category product candidates New medical concept with extraordinary safety Strategic partnerships in EU, Asia and USA Innovative treatments for local administration Press releases October 23, 2018Promore Pharma has had a successful meeting with the FDA regarding PXL01 October 1, 2018Promore Pharma has enrolled first patient in HEAL LL-37 in Poland September 6, 2018Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland September 3, 2018Promore Pharma Plans to Expand Indications of Therapeutic Peptide PXL01 in the Field of Dermal Scarring More Press Releases Interim report January – June 2018 Promore Pharma AB (publ) published its interim report for the second quarter 2018 on August 20, 2018. Report - English Report - Swedish Read the report Calendar November 21, 2018Redeye Life Science Seminar November 23, 2018Interim report January – September 2018 February 26, 2019Year-end report 2018 More Events The shareFNSE (PROMO): The Company Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need. Read more Vision The vision of Promore Pharma is to solve the global medical problems of scarring, adhesions and chronic wounds. Read more Market Within the global wound care market Promore Pharma’s product candidates are intended for the bioactive wound care segment. The bioactive wound care segment constitutes the fastest growing segment within the overall wound care market with a projected annual growth rate from 2015-2020 of 14 percent and is expected to reach USD 7.3 billion in 2020. Read more The Company Promore Pharma in Brief Vision and Strategy Market Team Board of Directors Projects Development Portfolio PXL01 – Prevention of Post-Surgical Adhesions LL-37 – Healing of Chronic Wounds Publications Investors Promore Pharma on Nasdaq First North The Share Financial Reports Press Releases Presentations and Events Calendar Subscribe Corporate Governance Corporate Governance General Meeting Nomination Committee The Board of Directors The Management Remunerations and Remuneration Committee Auditor and Audit Committee Articles of Association Media Press Releases News Imagebank Subscribe Contact Office Investors Media Promore Pharma AB. Address: Karolinska Institutet Science Park, Fogdevreten 2, SE-171 65 Solna, Sweden. Phone: +46 8 124 548 59. E-mail: info@promorepharma.com. Registration number: 556639-6809. Personal data About cookies Welcome to Promore Pharma AB’s website. In order to optimize your use of our website we use cookies. A cookie is a text file stored on your computer. If you want more information about what a cookie is, what the purpose of the cookie is and how you can block or delete cookies, please read the our cookie guidelines “About cookies”. By continuing, you agree to our use of cookies. Yes, I accept